Oncology News International April 2009 Vol. 18 No. 4

Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

A network meta-analysis of 3 clinical trials sought to compare zanubrutinib vs approved BTKis in relapsed/refractory chronic lymphocytic leukemia.

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS

3 Things You Should Know About Unresectable NSCLC

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

ONCOLOGY Staff

Fostering the Future of Psychosocial Care With World Psycho-Oncology Day

In first-line, EGFR-mutated NSCLC, targeted therapies such as osimertinib or amivantamab plus lazertinib are recommended.

Cristiane Decat Bergerot, PhD

April 14th 2025

Cemiplimab Continues to Show Benefit Vs Chemo in PD-L1 ≥50% NSCLC

Integrating psychosocial care into cancer care allows patients to receive emotional support, counseling, and coping strategies to help navigate treatment.

Multicancer Early Detection Test Showed Clinical Benefit, Minimal Distress

A 5-year follow-up of the phase 3 EMPOWER-Lung 1 showed the greatest survival benefits in patients with NSCLC who have a PD-L1 expression of 90% or more.

Zanubrutinib Shows Enhanced Efficacy vs Approved BTKis in R/R CLL

Patients with a cancer signal detected via multicancer early detection test demonstrated similar results to those who did not in the PATHFINDER cohort study.

Related Content

$A network meta-analysis of 3 clinical trials sought to compare zanubrutinib vs approved BTKis in relapsed/refractory chronic lymphocytic leukemia.$

Roman Fabbricatore

Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

A network meta-analysis of 3 clinical trials sought to compare zanubrutinib vs approved BTKis in relapsed/refractory chronic lymphocytic leukemia.

Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS

3 Things You Should Know About Unresectable NSCLC

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

ONCOLOGY Staff

Fostering the Future of Psychosocial Care With World Psycho-Oncology Day

In first-line, EGFR-mutated NSCLC, targeted therapies such as osimertinib or amivantamab plus lazertinib are recommended.

Cristiane Decat Bergerot, PhD

April 14th 2025

Cemiplimab Continues to Show Benefit Vs Chemo in PD-L1 ≥50% NSCLC

Integrating psychosocial care into cancer care allows patients to receive emotional support, counseling, and coping strategies to help navigate treatment.

Multicancer Early Detection Test Showed Clinical Benefit, Minimal Distress

A 5-year follow-up of the phase 3 EMPOWER-Lung 1 showed the greatest survival benefits in patients with NSCLC who have a PD-L1 expression of 90% or more.